Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Olutasidenib

Olutasidenib Phase 1/2 (glioma cohort)

Rigel · Phase 1/2 · Completed · Enrollment 93

NCT03684811

ArmPopulationDoseEstimandComparatorEfficacy
Olutasidenib 150 mg BIDrelapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable)150 mgSingle armn/robjective response rate: 8%, 2 of 25disease control rate: 48%, 12 of 25